Early access to Opti-mAb® technology addresses key developability risks and optimizes scFv stabilization.
Summary
Engineering multispecific antibodies often means working with scFvs that are elegant in design but challenging in practice. Instability, aggregation, and poor expression frequently emerge early, limiting manufacturability and slowing lead selection. evitria AG has partnered with AAX Biotech AB to provide access to Opti-mAb® in early development. This scFv-focused stabilization technology is designed to address key developability risks at the design and optimization stage before they become downstream problems.
See full technology spotlight by filling out the form.
